NURIX THERAPEUTICS, INC. (NRIX) Return on equity 2020–2025
NURIX THERAPEUTICS, INC. (NRIX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-49.1%FY2025 · since FY2020: -14.9% → -49.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -49.1% | -12.4 pp |
| FY2024 | -36.7% | +35.1 pp |
| FY2023 | -71.8% | -12.4 pp |
| FY2022 | -59.4% | -25.2 pp |
| FY2021 | -34.2% | -19.3 pp |
| FY2020 | -14.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice